On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Completes Acquisition of Quantitative Medicine LLC

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced it has completed its acquisition of Quantitative Medicine LLC (“QM”), a biomedical analytics and computational biology company, in an all-stock transaction valued at approximately $1.8 million. Cofounded by Drs. Robert Murphy and Joshua Kangas, … Continue reading “QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Completes Acquisition of Quantitative Medicine LLC”

Predictive Oncology Inc. (NASDAQ: POAI) Announces Acquisition of Soluble Therapeutics, BioDtech as it Continues Buildout of Precision Medicine Business

Predictive Oncology announced the acquisition of Soluble Therapeutics Inc. & BioDtech Inc. Acquired companies seek to enhance drug development process through the optimization of protein solubility and stability as well as through detection, removal of endotoxins The companies were acquired for consideration amounting to 125,000 common shares and waiving of $1.07 million promissory note issued … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Announces Acquisition of Soluble Therapeutics, BioDtech as it Continues Buildout of Precision Medicine Business”

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $2.2M Through Warrant Exercise

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Monday announced the closing of its previously announced transaction. According to the update, Predictive Oncology secured approximately $2.2 million in gross cash proceeds from the transaction, prior to deducting placement agent fees and offering expenses, … Continue reading “QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $2.2M Through Warrant Exercise”

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Leverages Unique Patient-Derived Platform to Assist Oncologists

Predictive Oncology (NASDAQ: POAI), through its Helomics subsidiary, is providing clinical decision support tools to support oncologists in personalizing cancer treatment. A recent article discussing the company further reads, “Through its unique patient derived (PDx) platform, which tests the drug response and biomarker profile of the patient’s own tumor, and its vast database of historical … Continue reading “QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Leverages Unique Patient-Derived Platform to Assist Oncologists”

QualityStocksNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Secures First Commercial Sale of its Unique Ovarian Cancer Cell Media

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its TumorGenesis division sold its first order of its unique ovarian cancer cell culture media for cancer cells collected from patient derived samples (“PDx”) through its distributor US Biological Corporation. According to the … Continue reading “QualityStocksNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Secures First Commercial Sale of its Unique Ovarian Cancer Cell Media”

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Financial Results for Q1 2020, Provides Business Update

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Monday reported financial results for the quarter ended March 31, 2020 and provided a business update. “We remain steadfast in our approach to assembling a portfolio of assets that leverages our unique collection of cancer … Continue reading “QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Financial Results for Q1 2020, Provides Business Update”

Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Acquisitions, Exclusive Database of Historical Tumor Data in Recent Interview

POAI boasts unique historical database documenting actual drug responses of tumors – the largest in the world with over 150,000 tumors across 137 types Drug discovery funding for subsidiary Helomics planned through relationships with large pharmaceutical companies Company planning to acquire two new biological firms in the precision medicine space Predictive Oncology Inc. (NASDAQ: POAI) … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Acquisitions, Exclusive Database of Historical Tumor Data in Recent Interview”

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Acquires Soluble Therapeutics, Inc. and BioDtech, Inc.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Tuesday announced the completion of the acquisitions of two wholly owned subsidiaries of InventaBioTech, Inc., Soluble Therapeutics, Inc. and BioDtech, Inc. Included in the acquisition were certain intellectual property relating to contract research organization (“CRO”) … Continue reading “QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Acquires Soluble Therapeutics, Inc. and BioDtech, Inc.”

Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiary a ‘Major Asset’ in Growing Precision Medicine Space

POAI addresses pressing need for a multi-omic approach in field of precision medicine Global precision medicine market is expected to reach total market value of approximately $84 billion by 2026 Predictive Oncology’s ‘claim to fame’ is its inventory of over 150,000 tumors covering over 137 types of cancer, with over 30,000 related to ovarian cancer In … Continue reading “Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiary a ‘Major Asset’ in Growing Precision Medicine Space”

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Applies Unique Database to Improve Cancer Outcomes

Predictive Oncology (NASDAQ: POAI), through its Helomics subsidiary, is leveraging its proprietary database of more than 150,000 tumor genomic and drug response profiles to improve cancer outcomes. An article discussing the company reads, “With a mission to improve the standard of care for cancer patients, Helomics’ TruTumor(TM) platform harnesses the power of the patient’s own … Continue reading “QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Applies Unique Database to Improve Cancer Outcomes”

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered